Abnormal hormonal signaling, particularly involving estrogen and progesterone receptors (ER and PR), can drive proliferation in hormone‐responsive tissues, contributing to tumor development, along with genetic and epigenetic alterations disrupting the tightly regulated processes of cell proliferation, apoptosis, and differentiation. The gene discussed is PGR; the disease is neoplasm.